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The Impact of Myoblast Transplantation on Collateral Capillary Arteriogenesis and Macrophage 
Phenotype  
 
Christine Hue Do 
 
Gangrene, pain, loss of limb function, amputation, and death are only few of the grievous 
consequences associated with peripheral arterial disease (PAD), a vascular disease caused by an 
obstruction that narrows the blood vessels. Since some patients have collateral vessels that can 
re-route blood to its downstream destination, much focus has been spotlighted upon discovering 
the mechanism of this process, termed arteriogenesis, as well as cell therapies to increase arterial 
diameter of collateral vessels. Since some patients do not have native pre-existing collateral 
vessels, another method to re-route blood is through arterialized collateral capillaries (ACC), 
which is the conversion of capillaries to arterioles. Because the delivery of pro-arteriogenic cell 
therapies did not have much clinical success, another candidate is needed to treat PAD: 
myogenic precursor cells. Preliminary, unpublished results demonstrated myogenic cell 
transplantation enhanced collateral capillary arterialization. Specifically, the diameter of 
arterialized collateral capillaries due to myoblast treatment is larger when compared to the 
vehicle alone and untreated groups. The current working hypothesis suggests that myoblasts and 
macrophages have a reciprocal paracrine interaction in which macrophages secrete cytokines and 
chemokines for the myoblasts to mature, and that certain genes in myoblasts are expressed as 
cytokines and chemokines to encourage macrophage recruitment and M2 macrophage 
polarization, which promotes arteriogenesis. To test this hypothesis, the expression of target 
genes in myoblasts would be measured using RNA sequencing and Western blotting for 
measuring proteins, macrophage phenotype and quantity would be determined in vivo along with 
vessel diameter with immunofluorescence staining. This senior thesis describes the studies that 
would need to be completed to test the hypothesis stated above, including example images from 
the immunofluorescence staining, detailed protocols, and candidate genes. 
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INTRODUCTION 
Preview: Due to the devastating impacts of peripheral artery disease (PAD) and the lack 
of clinical success of current arteriogenic therapies, differentiated muscle satellite cells are a new 
possible cell therapy. Unpublished results indicates that transplanting congenic primary 
myoblasts increases collateral capillary arteriogenesis. The working hypothesis to explain this 
observation is that myoblasts enhance arteriogenesis through paracrine interactions of signaling 
proteins and/or regulatory miR molecules. To test this hypothesis, the expression of target genes 
in myoblasts would be measured using RNA sequencing and Western blotting; the mouse model 
of PAD is induced by ligating the lateral feed artery of the spinotrapezius muscle; and the 
macrophage phenotypes, vessel diameters, and vessel count in vivo would be quantified with 
antibody staining.  
 
Figure 1. Peripheral artery disease (PAD). PAD is an ischemic condition in which plaque 
accumulation from atherosclerosis narrows blood flow. Adapted from [1]. 
 2 
Peripheral arterial disease (PAD) is the narrowing of arteries in the peripheral circulation 
due to an arterial atherosclerosis, leading to impaired perfusion to a patient’s lower extremities 
[2]. The plaque deposits from atherosclerosis accumulate in the peripheral circulation, which 
reduces the blood flow usually in the lower limbs (Figure 1) [3]. More than 200 million people 
worldwide have PAD, and its prevalence increases with age, reaching 20% amongst those over 
55, and certain factors (e.g., obesity, diabetes, high blood pressure, smoking) can increase the 
risk for PAD [4–6]. Health consequences associated with PAD are critical limb ischemia, 
gangrene, amputation, intermittent claudication, ulcers, myocardial infarctions, etc. [7]. Among 
these symptoms, intermittent claudication, which is leg pain while walking, is one of the most 
common. Treatment methods for PAD include revascularization and exercise training programs. 
Revascularization entails stenting, bypass grafting, or angioplasty surgical interventions. 
However, 20-30% of patients with critical limb ischemia are ineligible for revascularization due 
to comorbidities, and 25% perish within five years [8]. Those ineligible for revascularization 
methods may opt for limb amputation, but 20% pass away within six months [8]. Exercise is 
considered the ideal treatment method since it can naturally improve limb function without 
surgical intervention. However, intermittent claudication has discouraged many patients from 
complying with exercise therapy. Plus, exercise does not improve blood flow [9], so it should 
accompany surgical intervention to improve patient limb function and blood flow. In fact, a 
combined program of revascularization surgical intervention and exercise has been linked to 
increased walking distance and improved health-related quality-of-life scores [10]. In lieu of 
revascularization, promoting collateral arteriogenesis to improve patient limb function and blood 
flow may be a more viable option. Coupled with exercise programs, myoblast transplantation 
could be a useful therapy for those with intermittent claudication. 
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Collateral vessels, which help restore blood flow by bypassing major arterial obstructions 
and remodeling through arteriogenesis, enlarge to accommodate this redistribution of blood flow 
to the ischemic region (Figure 2) [10, 11]. After the occlusion of an artery, blood flow is 
redirected into collaterals, which increases shear stress in vessel walls and triggers collateral 
remodeling (Figure 3) [12, 13]. The elevated fluid shear stress activates arteriolar endothelial 
cells and increases the expression of adhesion molecules and chemokines such as MCP-1 to 
stimulate the proliferation of vascular smooth muscle cells (SMCs) and endothelial cells (ECs) 
and monocyte migration [12, 14, 15]. Mitogens secreted by macrophages promote cell 
proliferation and monocyte migration to further recruit more macrophages and continue this 
cycle of reciprocal paracrine interaction [16, 17]. 
 
Figure 2. Collaterals. Collateral vessels re-route blood around an occlusion or arterial 
obstruction to restore and normalize blood flow. Adapted from [11]. 
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Figure 3. Collateral Arteriogenesis. Collateral artery growth in response to arterial 
obstruction based on increased shear stress. Before an occlusion, blood flows through the 
conductance artery (left). During an occlusion, the conductance artery experiences decreased 
perfusion, which increases shear stress in the collaterals due to the blood flow redistribution 
(middle). In response to the occlusion, peri-collateral macrophages migrate to promote 
collateral remodeling into mature collateral arteries, which restores perfusion (right). Adapted 
from [14]. 
Some people have pre-existing collaterals, which lead to a lower risk of a cardiac event and 
increase in myocardial viability [16-18]. However, only about 30% have these pre-existing 
collaterals [19, 20]. For those without, there is also collateral capillary arteriogenesis, which 
arterializes arteriole-to-arteriole capillary collaterals that are a part of a highly-connected 
arteriolar network, which operates in a similar manner in terms of mechanisms and control 
pathways as those of arteriogenesis in pre-existing collateral vessels [24]. These arterialized 
collateral capillaries (ACC) are similar in appearance to capillaries yet have enlarged diameters 
and are covered with smooth muscle cells, and thus are arterioles. 
 Since arteriogenesis is a process mediated by growth factors, cytokines, and other 
signaling molecules, delivering these known factors to the ischemic area via intramuscular or 
intravenous injection is a therapeutic idea explored in both gene and protein therapy. Some pro-
arteriogenic factors that were delivered are vascular endothelial growth factor (VEGF), fibroblast 
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growth factor (FGF), hepatocyte growth factor (HGF), and monocyte chemoattractant protein-1 
(MCP-1). When VEGF is delivered via gene therapy or recombinant protein into animal models, 
limb ischemia was mitigated [22-24], tissue perfusion and blood flow recovery increased [25, 
26], and combined with FGF, elicited a synergistic effect upon collateral artery development and 
remodeling [23, 25, 27, 28]. Delivery of FGF yielded collateral artery growth [29, 30], increased 
vascular permeability and muscle perfusion [34], improved blood flow and functional collateral 
vessels [26, 32, 33], and increased arteriole density [37]. Therapeutic arteriogenesis by delivering 
HGF have been associated with increased limb tissue perfusion, pain relief, and ankle-brachial 
index [35, 36], yet these same studies performed in larger clinical trials yielded no significant 
findings to indicate lessened adverse events, wound healing, or amputations [35-38]. The 
chemokine process of MCP-1 encourages monocyte recruitment which secrete growth factors 
that aid in outward collateral remodeling [42], though the exact mechanism in which MCP-1 
promotes monocyte recruitment is unclear. Early animal studies involving intra-arterial catheter 
injections of MCP-1 via an osmotic minipump demonstrated increased collateral flow and 
proliferation of SMCs [43], increased collateral conductance [41, 42], improved peripheral 
conductance and ratio of peripheral over aortic blood pressure [46], well-developed collateral 
circulation [47], and blood flow recovery [45]. However, several studies have shown that 
intramyocardial injection of MCP-1 into the infarct border zone did not result in arteriogenesis 
[48], meaning MCP-1 did not improve myocardial infarctions via arteriogenesis. Plus, there are 
concerns of increasing pro-atherosclerotic macrophages in the plaque with MCP-1 delivery [46, 
47]. Despite promising animal studies of gene and protein therapy to induce arteriogenesis, these 
potential treatments had no significant reductions in intermittent claudication, amputations, or 
adverse events such as death.  
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 Because of the lack of clinical success in delivering pro-arteriogenic factors to treat PAD, 
a different therapy was established: cell transplantation. Instead of delivering multiple factors, 
local delivery of cells that secrete many cytokines, chemokines, and growth factors in 
appropriate doses into sites of injury or remodeling may be more efficient. The first candidate for 
cell transplantation was bone marrow derived mononuclear cells (BM-MNCs) due to the 
presence of stem cells with self-renewal and differentiation properties in this population of 
monocytes, lymphocytes, hematopoietic stem cells, and mesenchymal stem cells. In some animal 
ischemic models, congenic delivery of BM-MNCs improved collateral circulation and limb 
perfusion [51], differentiation of SMCs and ECs [52], blood flow recovery and collateral vessel 
formation [53], and reduced auto-amputation and improved limb salvage [54]. However, an 
unblinded and uncontrolled pilot study in humans resulted in no differences in long-term adverse 
events in half of the participants and even worsened leg pain [55]. Another pilot study resulted in 
two patients being re-admitted into the hospital for chest pain following the autologous bone 
marrow injection [56]. A randomized, controlled trial showed no improvement in ankle-brachial 
index, and transcutaneous oxygen pressure value [57]. The second iteration of cell therapy for 
peripheral ischemia was bone-marrow derived mesenchymal stem cells (BM-MSCs). In some 
animal ischemic models, BM-MSCs increased collateral diameters and vessel tortuosity [58], 
blood flow recovery and SMCs development [54, 55], increased collateral flow [61], and 
capillary arterialization [62]. Despite these positive outcomes, clinical trials performed upon 
humans have mixed results. BM-MSCs do not transdifferentiate into SMCs in animal models 
[62]. There was no effect of BM-MSCs improvement in terms of left-ventricular ejection at 18 
months [63]. There was no difference in ankle-brachial index when comparing the BM-MSCs 
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group to the control [64]. These promising therapies have encouraging pre-clinical results, but 
therapeutic clinical efficacy is limited.  
 Since bone marrow stem cells did not result in desirable clinical outcomes, cell types 
outside of the bone marrow should be considered. Another cell treatment for PAD was 
endothelial progenitor cells (EPCs). In men, the levels of circulating EPCs were a good predictor 
of vascular function and reactivity [65]. After transplanting human EPCs into mice with 
hindlimb ischemia, blood flow recovery, capillary density, and limb salvage ratio increased [66]. 
In a randomized, controlled pilot study, however, there was no difference in ankle-brachial index, 
wound healing, leg pain, and walking distance between the cell-treated group and the control 
[67]. Yet another potential alternative is myoblast transplantation. Arising from satellite cells 
during myogenesis, myoblasts are myogenic progenitor cells that are in the early stages of 
developing into a muscle cell and are primarily involved in skeletal muscle repair. Since satellite 
cells are activated by mechanical load, growth stimulus, and resistance exercise [68], pairing this 
cell therapy with exercise may improve leg pain and walking distance. Compared to bone 
marrow derived stem cells, satellite cells are native to the skeletal muscles, which allows for 
intrinsic factors and external cues within the muscle stem cell niche to control their behavior [68-
70]. Since bone marrow derived stem cells are not a part of this niche, they may be 
communicating less effectively to the surrounding cells and structures, which may contribute to 
decreased effectiveness as a cell therapy. After being activated from the quiescence state, these 
tissue resident stem cells recruit monocytes and macrophages. In order to enhance both vessel 
and muscle growth, the monocytes and macrophages secrete cytokines and chemokines to 
encourage the maturation of satellite cells into myotubes (Figure 4) [67, 68]. Myoblasts, in 
particular, have pro-angiogenic responses to induced ischemia through upregulation of VEGF 
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and angiopoietin, and the enhancement of neovascularization [71-73]; however, the effect of 
myoblasts upon arteriogenesis is still unclear. Recent studies have shown that satellite cells 
produce paracrine effects upon collateral vessel formation through EC and SMC proliferation, 
and blood flow recovery [74-77], thus displaying that myoblasts may also have pro-arteriogenic 
effects.  
 
Figure 4. Myogenesis. Process of tissue injury activating satellite cells into myoblasts. 
Monocyte and macrophage recruitment help muscle growth and maturation into myotubes. 
Adapted from [81]. 
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Though EC and SMC proliferation are common characteristics of arteriogenesis, 
macrophages are the primary regulators of arteriogenesis [79-81]. There are two ends of the 
macrophage phenotype spectrum: classically activated (M1) and alternatively activated (M2) 
[85]. M1 macrophages are pro-inflammatory with pathogen-killing capabilities, while M2 are 
anti-inflammatory and focus on tissue repair and cell proliferation [80, 81]. By releasing pro-
arteriogenic and anti-inflammatory cytokines, chemokines, and growth factors, M2 macrophages 
enhance arteriogenesis (Figure 5) [83-85].  
 
Since monocytes and activated satellite cells have reciprocal paracrine interactions [90], it is 
hypothesized that myoblasts secrete certain factors that promote arteriogenesis by inducing M2 
macrophage polarization. If the myoblasts do secrete pro-arteriogenic factors, then there must be 
certain genes that translate for these factors. Recent evidence has suggested that specific 
microRNAs (miRNAs), conserved non-coding regions of RNA molecules that regulate 
 
Figure 5. M2 macrophages giving rise to vessel maturation. Ischemic region induces several 
cytokines to be released, one of which polarizes M2 macrophages to release pro-angiogenic and 
pro-arteriogenic factors. Adapted from [89]. 
 10 
complementary mRNA sequences by binding to the 3’-untranslated regions of targeted mRNA to 
result in post-transcriptional gene silencing in which the mRNA is degraded or blocked from 
translation [91], are involved in a pathological process of PAD [92-96]. In fact, there are several 
myoblast genes that are correlated to various pro-arteriogenic responses, such as EC proliferation, 
EC migration, SMC proliferation, EC migration, monocyte recruitment, and macrophage 
polarization. EC proliferation is linked to miR-352 [97], miR-93 [98], miR-100 [99], miR-27a/b 
[100], miR-23 [101], miR-15b-5p [102], miR-155 [103], miR-let-7g [104, 105], miR-106b [106], 
miR-126 [107, 108], miR-495 [109], miR-329[109], miR-15a [110], miR-503 [111], miR-223 
[112], and miR-17~92 [113, 114]. EC migration is linked to miR-146a [115], miR-27a/b [100], 
miR-23 [101], miR-150 [116], miR-15b-5p [102], miR-106b [106], miR-126-3p [117], miR-126 
[107, 108], miR-495 [109], miR-15a [110], miR-352 [97], miR-503 [111], miR-223 [112], miR-
17~92 [113, 114], and miR-92a [118]. SMC proliferation is linked to miR-143-3p [119], miR-93 
[98, 120], and miR-199a-5p [121]. SMC migration has been linked to miR-100 [99]. Monocyte 
recruitment is linked to miR-199a-5p [122], miR-27b [123-126], and miR-146a [115]. 
Macrophage polarization has been linked to miR-93 through down-regulation of pro-
inflammatory cytokines [98, 127]. A table of these genes and their correlated pro-arteriogenic 
result is summarized in Table 1. Some miRNA target databases have found that one miRNA can 
regulate several gene targets, whereas a single gene could also be the target for several miRNAs 
though some studies have determined a one-to-one relationship between the miRNA and its 
target gene [91]. Other studies have suggested that a cluster of miRNAs can work in conjunction 
to regulate a gene [91, 128-129]. Based on the summary of myoblast miRNAs in Table 1, there 
are some miRNAs that have multiple pro-arteriogenic targets, as shown in Table 2. Most notable 
from this table is that miR-27b and miR-93 have the most pro-arteriogenic targets. miR-27b 
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results in the upregulations of EC proliferation, EC migration, and monocyte recruitment, while 
miR-93 is linked to upregulations of EC proliferation, SMC proliferation, and macrophage 
polarization.  













miR-352 miR-146a miR-143-3p miR-100 miR-199a-5p miR-93 
miR-93 miR-27a/b miR-93  miR-27b  
miR-100 miR-23 miR-199a-5p  miR-146a  
miR-27a/b miR-150     
miR-23 miR-15b-5p     
miR-15b-5p miR-106b     
miR-155 miR-126-3p     
miR-let-7g miR-126     
miR-106b miR-495     
miR-126 miR-15a     
miR-495 miR-352     
miR-329 miR-503     
miR-15a miR-223     
miR-503 miR-17~92     
miR-223 miR-92a     
miR-17~92      
 













miR-352 miR-352 -------- -------- -------- -------- 
miR-93 -------- miR-93 -------- -------- miR-93 
miR-100 -------- -------- miR-100 -------- -------- 
miR-27a/b miR-27a/b ------- -------- miR-27b -------- 
miR-23 miR-23 ------- -------- ------- -------- 
miR-15b-5p miR-15b-5p ------- -------- ------- -------- 
miR-106b miR-106b ------- -------- ------- -------- 
miR-126 miR-126 ------- -------- ------- -------- 
miR-495 miR-495 ------- -------- ------- -------- 
miR-15a miR-15a ------- -------- ------- -------- 
miR-503 miR-503 ------- -------- ------- -------- 
miR-223 miR-223 ------- -------- ------- -------- 
miR-17~92 miR-17~92 ------- -------- ------- -------- 
-------- miR-146a ------- ------- miR-146a ------- 
------- ------- miR-199a-5p ------- miR-199a-5p ------- 
 
 12 
The working hypothesis for this thesis is that there are some miRNAs in myoblasts that 
affect arteriogenesis. To test the effects of myoblast-enhanced arteriogenesis, the following 
methods would be used: RNA sequencing of miRNAs in myoblasts; measuring the expression of 
proteins and miRNA candidates; inducing a PAD murine model through ligation surgery; 
myoblast transplantation following the ligation surgery; and after cell transplantation, measuring 




All pilot procedures were performed according to protocols approved by Cal Poly’s 
Institutional Animal Care and Use Committee (IACUC). Male BALB/C (n=12) mice (Taconic 
Farms, Oxnard, CA) and ICR mice were used for all experiments. All mice were housed at the 
University Vivarium in microisolator cages with access to water, food, and enrichment (bedding 
and ‘mouse house’). This facility operates on a 12-hr light:12-hr dark cycle with temperature-
controlled rooms. All animals were inspected daily. The ICR mice were used during antibody 
staining training. The BALB/c mice were divided into the following groups: ligation surgery 
only control (n=4), vehicle (n=4), and myoblast-vehicle transplantation (n=4).  
 
Surgery 
The purpose of the surgery is to model ischemia and the growth of collateral arteries and 
macrophage migration by ligating the spinotrapezius lateral feed artery. Mice were anesthetized 
in the induction chamber with 5% isoflurane mixed into oxygen and flowing at 3 L·min-1 oxygen 
flow. After checking the mouse’s righting reflex, the mouse was weighed and placed on the 
preparatory stage with 2-3% isoflurane mixed into oxygen and flowing at 0.5-1.5 L·min-1. 
Ophthalmic ointment was applied to the corneas to prevent desiccation. Trimming clippers and 
depilatory cream were used to remove hair bilaterally on the dorsal surface. The area was 
disinfected with chlorhexidine diacetate. The mouse received a subcutaneous buprenorphine 
(0.075 mg/kg) injection as an analgesic. After transferring the mouse to the surgical platform, the 
mouse’s core temperature was monitored by rectal thermistor probe and maintained at 35˚C and 
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kept constant with a heating pad. An initial incision was made on the lateral edge of the 
spinotrapezius muscle parallel to the spine (Figure 6).  
 
Figure 6. Location of Ligation and Myoblast-Vehicle Treatment Delivery. The location of 
the spinotrapezius ligation is lateral to the muscle, while the treatment delivery location is above 
the ligation site. Adapted from [130]. 
 
After blunt dissecting the fascia and undermining the superficial fat pad to find the deep fat pad 
under the spinotrapezius muscle, the artery-vein pair was found. After separating the artery from 
the pair, the artery was ligated in two locations using silk sutures and transected between the 
ligatures. The incision was closed using a 7-0 prolene suture. This same surgical procedure was 
repeated on the sham side, though the artery was not ligated nor transected. The mouse was 
given another dose of a buprenorphine injection following the procedure. Injections were also 
given 24- and 48-hours post-ligation and more if necessary. A more detailed protocol of the 
ligation surgery is in Appendix A1. Example images of arterialized collateral capillaries and 






Figure 7. Example images arterialized collateral capillaries (ACC) following ligation 
surgery. Adapted from [130]. A) Female mouse ligated with ACC in red. B) Female mouse 
ligated with capillaries in blue. C) Male mouse ligated with ACC in red. D) Male mouse ligated 




The purpose of culturing satellite cells into myoblasts is to have cells ready for 
transplantation. Satellite cells would be isolated from young male C57BL/6 mice were from the 




Collagenase and placed in a tissue culture media dish for myofiber separation. To isolate 
myofibers, the muscles were gently mechanically agitated by tituration. Live fibers were placed 
in cell culture flask. More detailed protocols about satellite cells and myoblasts are in 
Appendices A2 for satellite cell isolation and A3 for myoblast expansion. Myoblast cultures 
were assessed through the phase-contrast microscope daily, feed every two days, and passaged 
every 3-5 days. Directly after satellite cell isolation, however, feeding and passage does not 
occur until day 5 and 7, respectively. Once cells appeared to have a myoblast morphology, they 
were either frozen or seeded onto the gelatin vehicle for transplantation. More detailed protocols 
about cell culture are in Appendices A4 for solution preparation, A5 for cell passage and feeding, 
and A6 for cell freeze and thaw.  
 
Gelatin Preparation and Myoblast Transplantation 
The purpose of preparing a gelatin hydrogel is to form a vehicle that keeps cells viable 
during the transplantation process. A 10% gelatin vehicle would be prepared and polymerized in 
a 24-well plate to encourage cell viability and attachment. After polymerization, the gelatin was 
cross-linked with 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide at 4˚C overnight. After 
myoblasts were seeded onto the gelatin, the vehicle was incubated in growth media at 37˚C prior 
to transplantation. A more detailed protocol is in Appendix A7.  
After the ligation surgery, blunt dissection was performed under the spinotrapezius 
muscle to create a space for insertion (Figure 6). A gelatin disc was cut with a biopsy punch (1.5 




After 7 days post-surgery, all mice were euthanized by exsanguination and fixed with 
paraformaldehyde in preparation for muscle immunofluorescence staining. Prior to the 
euthanasia, the surgical wound was opened, and connective tissue around the spinotrapezius 
muscle was gently removed. After performing a thoracotomy, a 20G needle connected to 40 mL 
of vasodilator solution was pierced into the apex of the left ventricle (Figure 8); this cocktail was 
composed of 0.1 unit·mL-1 heparin (MWI Animal Health), 1.5 x 10-6 mol·mL-1 adenosine 
(A9251, Sigma-Aldrich), 2.5 x 10-5 mol·mL-1 sodium nitroprusside (71778, Sigma-Aldrich), and 
38 mL PBS. This solution was infused at a rate of 5 min·mL-1 with a syringe pump to clear the 
circulation and fully dilate the vasculature. After clearing the circulation, 4% paraformaldehyde 
was perfused at a rate of 4 min·mL-1 to fix the tissues and muscles and prevent decay. Muscles 
were resected and stored in PBS at 4˚C until stained. A detailed protocol is in Appendix A8.  
 
Figure 8. Needle Piercing Apex of Left Ventricle during Perfusion Fixation. 
 
Immunofluorescence Staining and Imaging 
All muscles were permeabilized in 2% Triton X-100 (detergent, 97063-996, VWR) for 2 
hours. Then, the spinotrapezius muscles were immunostained with antibodies to visualize 
arteriole and macrophages. To label smooth muscle actin present on arterioles, 1:200 smooth 
muscle anti-actin (clone 1A4 Cy3 antibody, C6198, Sigma-Aldrich) was used. To label 
capillaries, 1:100 isolectin GS-1B4 (Alexa Fluor 647, I32450, Invitrogen) was used. To label all 
macrophages, 1:100 anti-CD68 (Alexa Fluor 488 FA-11, 53068180, eBioscience at Fisher Sci) 
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was used as a pan-macrophage marker. To label M1 macrophages, 1:200 anti-CD11c (Alexa 
Fluor 532 N428 Clone, 58011482, Fisher Sci) was used. To label M2 macrophages, 1:200 anti-
CD206 (Alexa Fluor 594 C068C2 clone, 141726, BioLegend) was used. All antibodies were 
prepared in conjunction in PBS with 0.1% Triton X-100, and 2% BSA (A2153, Sigma-Aldrich) 
to permeabilize plasma membranes and block nonspecific binding, respectively. This antibody 
solution was incubated at 4˚C with each muscle for 24 hours. The muscles were washed with 
0.1% Triton X-100 4 times for 10 minutes each at room temperature and in PBS once for 30 
minutes. Muscles were mounted on incubation chambers, microscope slides with silicone casing, 
with 50/50 PBS/glycerol solution. The slides were imaged on a confocal microscope (Olympus 
FV-1000, Olympus) using the 10x and 20x lens objectives. Regions of interest that were imaged 
are in Figure 9, chosen specifically to observe the ischemic and perfused arterialized collateral 
capillaries (ACC) of arteriolar trees in the muscle [130]. A detailed protocol is in Appendix A9. 
Example images of αSMA-stained arterioles, lectin-stained capillaries, CD68-stained 
macrophages, and their composites are in Figure 10. 
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Figure 9. Muscle Imaging Regions. Spinotrapezius muscles were imaged at three locations 
between arteriolar trees where ACCs are. Scale bar is 1 mm. Red is arteriole staining, while the 











   
   
   
Figure 10. Immunofluorescent stained arterioles, capillaries, and macrophages. (A-C) 
Composites of arterioles, capillaries, and macrophages. (D-F) αSMA-stained arterioles in red.  
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Image Analysis 
 FIJI ImageJ Version 2.0.0 image software was used to quantify confocal images. The 
images were split into three channels based on lasers. The z-slices were collapsed into max 
intensity based on the number of slices. Each channel was colorized accordingly: red for αSMA-
stained arterioles, blue for lectin-stained capillaries, green for CD68-stained macrophages, 
yellow for CD206-stained M2 macrophages, and orange for CD11c-stained M1 macrophages. 
The brightness and contrast were adjusted to limit background staining. αSMA-positive vessels 
and lectin-positive vessels were hand-counted in the compressed image. To determine the max 
ACC diameter, the largest ACC was found, and a line was drawn perpendicularly across the 
vessel and measured (Figure 11a). To quantify macrophages, the images were converted to 
binary and analyzed for particles using a cell counter (Figure 11b). Example data measured from 
Figure 10 is displayed in Table 3.  
 
 
Figure 11. Image Analysis of Vessel Diameter and Macrophage Count. A) Vessel diameter 





Table 3. Vessel diameter, vessel count, and macrophage count of Figure 10. 
αSMA - Vessel Diameter (µm) Lectin – Vessel Count CD68 – Macrophages Count 
29.1 25 1047 
31 26 416 
4.45 29 303 
 
Statistical Methods 
MINITAB 19 Version 19.2020.2.0 statistical software for Macintosh was used for 
statistical analysis. Differences in # of ACC, maximum diameter, macrophage amount and 
phenotype in sham and ligated muscles were determined by independent t-tests. One-way 
ANOVA and post-hoc Tukey test determined differences between the ligation only, vehicle, and 
myoblast-vehicle groups in # of ACC, maximum diameter, CD68-, CD11c-, and CD206-positive 
cells in sham and ligated muscles. A p<0.05 indicated statistical significance. Data are presented 




Due to the abominable consequences of peripheral artery disease such as gangrene, limb 
amputation, and death, a therapy is needed to treat peripheral artery disease and re-route blood 
downstream. A method to bring blood downstream is through arteriogenesis, which is the 
remodeling of collateral vessels to increase vessel diameter and restore blood flow. Despite the 
various cell therapies that have been identified to aid arteriogenesis, they have not yielded 
positive clinical outcomes. Preliminary, unpublished data suggests that using myogenic precursor 
cells can promote arteriogenesis. It is hypothesized that the microRNAs from these cells are 
related to smooth muscle cell proliferation, smooth muscle cell migration, endothelial cell 
proliferation, endothelial cell migration, monocyte recruitment, and macrophage polarization; all 
of which are markers of successful arteriogenesis. This proposal seeks to test this hypothesis 
through RNA sequencing for candidate genes, measuring proteins via Western Blotting, murine 
model of PAD by artery ligation surgery, cell transplantation, and immunofluorescent staining to 
quantify vessel diameter changes and macrophage phenotypes.   
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Appendix A: Experimental Protocols 








To excise whole mouse Extensor Digitorum Longus (EDL) muscles, isolate individual live 
myofibers from whole muscles, and plate live myofibers in culture conditions to facilitate the 
primary culture of myoblasts. 
 
Necessary Material
 Wash media (10% FBS in Base Media) 
 Base media (1% Pen-Strep in HAMs F10) 
 Growth media (20% FBS in Base Media) 
 SB 203580 working solution (5 mM) 
 bFGF working solution (1μg/mL) 
 Collagenase II solution (2mg/mL) 
 Horse Serum (HS) 
 ECM coating solution (1:100) 
 18 MΩ Water 
 T 12.5 flask (cell culture treated) 
 10 cm TC dishes (x5) 
 15 mL conical tubes 
 Sterile Filter System 
 Sterile PBS (1x) 
 P1000 micropipette aid and tips 
 P20 micropipette aid and tips 
 Standard pattern forceps 
 Curved iris scissors 
 5/45 Forceps (x2) 
 Beveled long bore glass pipettes  
 Cotton swabs 
 2x2, 4x4 gauze pads 
 Isopropyl Alcohol (IPA) 
 Styrofoam working surface 
  
Mouse Information 





TC Dish Preparation 
1. ___ Coat a T12.5 with 0.5 mL ECM coating 
2. ___ Allow final plate to coat overnight on rocking platform (~ 10 rpm) 
3. ___ In the morning wash plate with sterile PBS 
a. 10 minutes per wash on rocking platform (~ 10 rpm) 
b. 2 washes 
c. Wash with wash media (Sterile filter media) 
 
Collagenase Incubation Solution 
1. ___ Weigh out 6 mg of type II collagenase  
2. ___ In BSC combine with 3 mL of Base Media 
3. ___ Resuspend well 
 
Muscle Fiber Wash Plates 
1. ___ Defrost aliquot of HS 
2. ___ In BSC, Coat 4x 10cm dishes in HS 
a. Label TC dishes 1-4 
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b. Pipette 7 mL of HS into first 10 cm dish 
c. Transfer HS between dishes 
d. Place remaining HS in 15 mL conical and place in 37⁰C water bath 
e. Aspirate excess HS from TC dishes 
3. ___ Place 15 mL of wash media into Dish 1 
4. ___ Place 5 mL of wash media into Dishes 2-4 
5. ___ Warm plates in 37⁰C, 5% CO2 incubator 
 
Muscle Excision – Extensor Digitorum Longus (EDL) 
1. ___ Euthanize mouse 
2. ___ Use insulin syringe needles to secure fore and hind limbs to Styrofoam working 
surface 
3. ___ Thoroughly spray hindlimbs with IPA  
4. ___ Carefully remove the skin of both hindlimbs 
a. The hindlimb should be exposed from the knee joint to the midpoint of each foot 
5. ___ Carefully remove connective tissue around the Tibialis Anterior (TA) Muscle 
a. Make sure to expose the origin of the EDL at the knee 
6. ___ Create a pocket deep to the distal TA tendon below the ankle  
7. ___ Cut the distal TA tendon  
8. ___ Holding the TA by its distal tendon, pull it towards the knee cutting away connective 
tissue as needed to separate it from the EDL 
9. ___ Cut the TA at its origin and set aside to expose the EDL 
10. ___ Create a pocket deep to the distal EDL tendon 
11. ___ Cut the Distal EDL tendon  
12. ___ Holding the cut tendon, carefully pull EDL towards the knee separating it from the 
surrounding tissue 
a. Avoid stretching the muscle as it will damage individual myofibers 
13. ___ Cut the proximal EDL tendon 
a. Tendon to Tendon isolation is critical to maintain fiber integrity 
14. ___ Place EDL muscle into 3.0 mL of collagenase solution 
15. ___ Repeat process for contralateral hindlimb 




1. ___Place 15 mL conical with EDL muscles and collagenase in 37⁰C water bath 
2. ___ Repeatedly invert the 15 mL conical for every 10 min of incubation 
3. ___ Incubate for 10 min 
a. Digestion can take between 10-30 min depending upon collagenase activity 
4. ___ Following 10 min, remove 15 mL conical every 5-10 min and inspect for proper 
digestion 
a. Use dissecting microscope light on brightest setting for lighting 
b. When properly digested individual myofibers should begin to protrude from the 
surface of the muscle belly 
c. If the muscle appears fuzzy under a dissecting microscope or individual fibers 
appear fat and milky in color, the muscle has been overdigested 
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5. ___ Upon proper digestion level, remove 15 mL conicals with HS and muscles from the 
water bath 
6. ___ Spray conicals down with IPA 
7. ___ Remove dish 1 from incubator 
8. ___ Coat glass pipettes in HS 
9. ___ Use glass pipettes to remove muscles from the 15 mL conical and transfer into the 
first dish 
a. Place both muscles into the first dish 
b. Place collagenase solution back into the water bath (in case further digestion is 
needed) 
10. ___ Use glass pipettes to dissociate muscles 
a.  Progressively use smaller bevel pipettes as the muscle becomes more dissociated 
b. The muscle should only be washed with media or gently pipetted up and down 
11. ___ Coat P1000 pipette tips with HS  
12. ___ Use a dissecting scope and P1000 pipette to pick out individual live myofibers from 
the dish 
a. Live myofibers will appear shiny or clear and be straight or crinkly 
b. Dead myofibers will appear opaque and bent or short  
13. ___ Place all live fibers in the next numbered dish 
a. Muscles should not remain out of the incubator for more than 10 min 
14. ___ Repeat transfer process for the other wash dishes 
15. ___ Transfer fibers as described into the ECM coated dish 
16. ___ In a BSC, add 2 μL bFGF solution per 1mL of media 
17. ___ In a BSC, add 2 μL P38 inhibitor solution (5mM) per 1mL of media 
18. ___ Place final dish back in the incubator 
a. Myoblasts should begin to migrate from the myofibers within 3 days 
b. Feed after 5 days (Partial media change performed by transferring old media into 
a conical with 5mL of fresh warm media and transferring 5mL of the solution into 
the flask) 




 EDL muscles will have individual fibers protruding from the surface and slightly 
separate in the body of the muscle when properly digested 
 The use of a wash dish (dish 4) is only necessary if a large number of dead or fragments 
of fibers are impeding the aspiration of live fibers only. You only want to aspirate live 
fibers 
 Cells should be passed when large, dense (80% confluent) colonies appear around fibers. 
If cells start to elongate (starting to differentiate), they should also be passed
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Appendix A3: Myoblast Expansion Protocol 
 
  
Primary Myoblast Expansion Protocol 
Date:    
 
Purpose: To expand primary mouse myoblasts from live Extensor Digitorum (EDL) muscle fibers 
 
Necessary Materials: 
• Growth Media (20% FBS in Base Media) 
• SB 203580 working solution (10 mmol) 
• bFGF working solution (1μg/ml in PBS) 
• Cell Dissociation Solution - EDTA (Fisher 13151014) 
• Trypsin/EDTA (0.05% Invitrogen 25300-062) 
• PBS (-/-, Ca+2, Mg+2) 
• ECM coated flask 
 
1. ___ Obtain an ~80% confluent culture vessel 
a. myoblasts will begin to differentiate and form myotubes as they approach confluency 
2. ___ Clean Phase Contrast Microscope with 70% v/v Isopropanol (IPA) 
3. ___ Image save pictures of the culture with a phase contrast microscope 
4. ___ Determine passage ratio to be used 
a. myoblasts should not be split at a ratio higher than 1:3 
5. ___ Choose passaging method based upon goals and culture conditions 
a. use Trypsin for: 
i. for better cell distribution, single cell suspension 
ii. for a confluent flask with low overall confluency (1:1 pass) 
b. use EDTA for: 
i. preservation of surface receptors (integrins) 
ii. selective passaging (more differentiated cells will more strongly adhere) 
Trypsin Passaging 
1. ___ Warm Trypsin and Growth Media in 37C H2O bath immediately before use 
2. ___ Aspirate media from culture vessel 
3. ___ Wash with PBS (-/-) and aspirate 
4. ___ Add warm trypsin 
a.  0.04 ml/cm2 surface (T12.5 - 0.5 ml, T75 - 3 ml) 
5. ___ Immediately place in incubator for ~2 min 
6. ___ Observe with phase contrast microscope 
a. cells should begin to ball up and become phase bright 
7. ___ Hit the flask repeatedly to dislodge weakly adherent cells 
8. ___ Observe under the phase contrast microscope to ensure detachment of all cells 
a. If cells are still attached, return them to the incubator for an additional min and repeat 
9. ___ Add the same volume of Growth Media as trypsin to stop enzymatic cleavage 
10. ___  Wash the surface of the culture vessel with the cell suspension 
11. ___ Label a 15 ml conical tube and transfer the cell suspension 
12. ___ Centrifuge at 300g for 5 min to create a cell pellet 
13. ___ Aspirate media from the conical 
a. be careful to avoid aspirating the pellet 
14. ___ Resuspend in the volume of growth media (+ factors) appropriate for the chosen passage ratio 
15. ___ Repeatedly pipette up and down to break of cell clumps 
16. ___ Rock the culture vessel repeatedly:  forward/back and left/right to evenly disperse the cells 
a. Even cell distribution can be checked under the phase contrast microscope 
17. ___ Place in incubator 




Appendix A4: Cell Culture Solution Preparation Protocol 
 
Solution Preparation  
Purpose: 




 Hams F10 Nutrient Mixture 
(SH3002501) 
 Fetal Bovine Serum (FBS)- Fisher 
(SH3091003IR) 
 basic Fibroblasts Growth Factor 
(bFGF)- Fisher (CB40060) 
 SB 203580 (P38/MAPK inhibitor) – 
Fisher (120210) 
 Reconstituted Powdered DMEM-
Fisher (31600034) 
 ECM (E1270-1ML) 
 Penicillin/Streptomycin (PenStrep)- 
Omega  
(PS-20 / 500) 
 18 MΩ H2O 
 Sterile PBS (1x) 
 1 M Hydrochloric Acid (HCL) 
 1 M Sodium Hydroxide (NAOH) 
 Sodium Bicarbonate (NAHCO3) 
 Sterile Filter (low protein binding) 
 
bFGF working solution 
1. ___ In a Biological Safety Cabinet (BSC) 
dilute bFGF in 0.1% BSA in PBS to a final 
concentration of 1μg/mL 
2. ___ Aliquot into 1.5 ml micro centrifuge 
tubes 
a. 50 μl, 100μl aliquots recommended 
b. Store at -20C for 3 months 
c. use upon thawing if possible, avoid 
additional freeze/thaw cycles 
SB 203580 working solution 
1. ___ In a BSC dilute in sterile DMSO to a 
final concentration of 5 mM 
2. ___ Aliquot into 1.5 ml micro centrifuge 
tubes 
a. 50 μl, 100μl aliquots recommended 
b. Store at -20C for 1 month 
c. use upon thawing 
ECM Coating Solution 
1. ___ Obtain ECM from -20C freezer 
2. ___ Thaw in 4C fridge (prevent gelation) 
3. ___ Keep ECM on ice at all times to 
prevent gelation 
4. ___ In BSC dilute ECM 1:200 in Hams 
F10  
5. ___ Aliquot remaining ECM into 1.5mL 
micro centrifuge tubes  
a. Avoid multiple freeze/thaw 
cycles 
Base Media 
1. ___ In a BSC add 5 mL Penstrep to 500 
mL bottle of Hams F10 
2. ___ Label Base Media and store up to 3 
months at 4C 
Wash Media 
1. ___ In BSC add FBS to Base media 
(10% FBS v/v) 
2. ___ Sterile filter media (optional)  
3. ___ Label Wash media and store at 4C 
a. only heat aliquots in 37C H2O 
bath immediately before use 
Growth Media  
1. ___ Obtain Wash Media (only make 
enough to use for up to 1 week) /  
2. ___ Add bFGF working solution @ 2ul 
to every 1ml of media  
3. ___ Add SB 203580 working solution @ 
2ul to every 1ml of media 
4. ___ Label Growth media and store at 4C 
a. only heat aliquots in 37C H2O 
bath immediately before use 
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Appendix A5: Cell Culture Protocol 
 
General Cell Culture Protocol 
Materials 
 Flask 
 Pipet-Aid & Serologicals 
 Media 
 Trypsin (Myoblasts: EDTA) 
 15ml conical 
 
Cell Passing 
1. Obtain new flask aseptically 
2. Label new flask with cell type, passage number, initials, and date 
3. Obtain media  
4. Transfer media to new flask & place in incubator for 30 minutes 
5. Transfer media to 15-ml conical (for deactivating trypsin) & place in water bath for 15 
minutes 
6. Obtain trypsin & place in water bath 
7. Vortex trypsin thoroughly to activate enzyme 
8. Aspirate media from old flask 
9. Transfer PBS to old flask (5-10 ml) and rinse 
10. Pipet-mix trypsin & transfer to old cells; incubate ~5min 
a. 3ml to T75 
b. 0.5ml to T12.5 
11. Retrieve new flask 
12. Inspect dissociation in old flask 
13. Once dissociated, add inactivation media and titurate 6-8x 
a. 12ml to T75 
b. Max 5ml to T12.5 
14. Aspirate entire contents & transfer to new flask 
15. Gently mix cells by tilting the flask and place in incubator 
 
Cell Feeding 
1. Aliquot media into 15ml conical and place in water bath for 15 minutes 
a. 12ml for T75 
b. Max 5ml for T12.5 
2. Aspirate old media out of flask 
3. Transfer warm fresh media into the flask 
4. Lightly swish media in flask 










Appendix A6: Cell Freeze/Thaw Protocol 
 




 1mL Cryovials 
 Sterile filter 
 15mL conical 
 100μL vial 




 Trypsin (Myoblasts: EDTA) 
 AO/PI stain (Cell count) 
 Flask 
 P1000 
 Pipette aid + Serologicals 
 
Freeze 
1. Make freeze media (5ml). 70%DMEM 20%FBS 10%DMSO, sterile filtered. 
2. Obtain trypsin & place in water bath 
3. Vortex trypsin thoroughly to activate enzyme 
4. Aspirate media from old flask 
5. Transfer PBS to old flask (5-10 ml) and rinse 
6. Pipet-mix trypsin & transfer to old cells; incubate ~5min 
a. 3ml to T75 
b. 0.5ml to T12.5 
7. Inspect dissociation in old flask 
8. Once dissociated, add inactivation media and titurate 6-8x 
a. 12ml to T75 
b. Max 5ml to T12.5 
9. Aspirate entire contents & transfer to 15mL conical 
10. Transfer 18μL into 100μL vial 
11. Centrifuge solution at 200g (0.2 rcf) for 6 minutes 
12. Add 2μL of AO/PI solution to 100μL vial. Transfer to counting slide and count 
13. Aspirate media leaving pellet of cells and resuspend in corresponding amount of freeze media (1 
million cells per 1mL) by triturating 
14. Aliquot 1mL of cell solution into each cryovial 
15. Quickly move to cooling liner and store at -80°C overnight 
16. Transfer to liquid nitrogen storage 
Notes 
 Myoblast freeze media: 90%FBS 10%DMSO 
 
Thaw 
1. Transfer media to new flask & place in incubator for 30 minutes (label flask) 
2. Transfer 9ml of media to 15-ml conical (for deactivating DMSO) & place in water bath for 15 
minutes 
3. Remove cryovial from Dewar and thaw in water bath by swirling 
4. Transfer cell solution into 9ml of warm media and triturate (work fast after thawing as DMSO is 
toxic to cells) 
5. Centrifuge solution at 200g (0.2 rcf) for 6 minutes 
6. Aspirate media leaving pellet of cells and resuspend in 1ml of media by triturating 
7. Transfer cell suspension into T75 with 12ml of prewarmed media 
8. Lightly swirl flask to ensure even cell distribution and place in incubator 
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Appendix A9: Spinotrapezius Muscle Staining and Imaging Protocol 
 
 
 
